Tadalafil Femalefil was withdrawn primarily due to concerns about its safety and effectiveness in women. While Tadalafil is well-established for treating erectile dysfunction in men, its use in women lacked sufficient clinical evidence to support its benefits for sexual dysfunction. Regulatory authorities often prioritize safety and efficacy, and without robust data, the product was not approved for women. Additionally, concerns over potential side effects and interactions in women contributed to the decision.
